Advising GSK on its strategic collaboration with CureVac
20 July 2020
An A&O team comprising UK, German, U.S. and Dutch lawyers is advising GlaxoSmithKline (GSK) on its strategic collaboration with German biotech company CureVac for the research, development and commercialisation of mRNA-based vaccines and monoclonal antibodies targeting infectious diseases. A&O also advised GSK on its equity investment of EUR150 million into CureVac as part of the transaction.
The A&O team was led by partners Peter Banks and Nigel Parker in the UK and partner Michael Weiss in Germany, alongside GSK relationship partner Matthew Appleton. Partners Ellen Braun (Antitrust, Hamburg), Christiaan de Brauw (M&A, Amsterdam), Alexander Veith (M&A, Munich), Stephen Besen (M&A, New York) and Marc Plepelits (ECM, Frankfurt) assisted on this transaction.